Raymond James & Associates Sells 2,658 Shares of BioNTech SE (NASDAQ:BNTX)

Raymond James & Associates reduced its stake in BioNTech SE (NASDAQ:BNTX – Get Rating) by 11.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,364 shares of the company’s stock after selling 2,658 shares during the period. Raymond James & Associates’ holdings in BioNTech were worth $2,747,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Captrust Financial Advisors increased its stake in shares of BioNTech by 6.9% during the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company’s stock valued at $159,000 after purchasing an additional 69 shares in the last quarter. Centaurus Financial Inc. increased its position in shares of BioNTech by 5.2% during the first quarter. Centaurus Financial Inc. now owns 1,448 shares of the company’s stock valued at $247,000 after acquiring an additional 71 shares in the last quarter. First Republic Investment Management Inc. increased its position in shares of BioNTech by 1.8% during the second quarter. First Republic Investment Management Inc. now owns 6,793 shares of the company’s stock valued at $1,013,000 after acquiring an additional 117 shares in the last quarter. Midwest Professional Planners LTD. increased its position in shares of BioNTech by 10.6% during the second quarter. Midwest Professional Planners LTD. now owns 1,779 shares of the company’s stock valued at $265,000 after acquiring an additional 170 shares in the last quarter. Finally, Cibc World Market Inc. increased its position in shares of BioNTech by 6.4% during the first quarter. Cibc World Market Inc. now owns 2,983 shares of the company’s stock valued at $509,000 after acquiring an additional 180 shares in the last quarter. 15.29% of the stock is owned by institutional investors.

BioNTech Trading Up 2.0 %

Shares of BioNTech stock opened at $142.79 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.37 and a quick ratio of 5.30. BioNTech SE has a 1-year low of $117.08 and a 1-year high of $189.07. The company’s fifty day simple moving average is $160.52 and its 200-day simple moving average is $152.74. The stock has a market capitalization of $34.65 billion, a PE ratio of 3.23 and a beta of 0.26.

BioNTech (NASDAQ:BNTX – Get Rating) last released its earnings results on Monday, November 7th. The company reported $7.04 earnings per share for the quarter, beating analysts’ consensus estimates of $3.66 by $3.38. BioNTech had a net margin of 55.72% and a return on equity of 66.45%. The company had revenue of $3.46 billion for the quarter, compared to analysts’ expectations of $1.90 billion. During the same quarter in the previous year, the company earned $14.56 EPS. BioNTech’s revenue for the quarter was down 43.1% on a year-over-year basis. As a group, equities analysts anticipate that BioNTech SE will post 35.38 earnings per share for the current year.

Wall Street Analyst Weigh In

BNTX has been the subject of several analyst reports. JPMorgan Chase & Co. set a $148.00 price target on shares of BioNTech in a research report on Wednesday, January 11th. Canaccord Genuity Group reduced their price target on shares of BioNTech from $200.00 to $191.00 and set a “buy” rating for the company in a research report on Tuesday, November 8th. UBS Group set a $168.00 target price on shares of BioNTech in a report on Tuesday, November 15th. The Goldman Sachs Group set a $177.00 target price on shares of BioNTech in a report on Monday, January 16th. Finally, Morgan Stanley raised their target price on shares of BioNTech from $194.00 to $203.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 8th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $208.69.

BioNTech Company Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.